Results 181 to 190 of about 33,763 (228)

Efficacy and safety of respiratory strength and endurance training in patients with myotonic dystrophy type 1 (DM1): a randomized controlled trial. [PDF]

J Neurol
Wenninger S, Heidsieck E, Wirner-Piotrowski C, Mijic M, Garcia-Angarita N, Gutschmidt K, Mendelshohn DH, Schoser B.   +7 more
europepmc   +1 more source

Synthesis of Janus Bases for Targeting C‑G and U-U Pairs of CUG-RNA Repeats Associated with Myotonic Dystrophy Type 1. [PDF]

ACS Omega
Thadke SA, Perera JDR, Thrikawala SW, Ly DH.   +3 more
europepmc   +1 more source

Assessing the Safety and Efficacy of Lamotrigine as Anti-myotonic Agent in Myotonic Dystrophy Type 1 (DM1): A Longitudinal, Open-Label, Pilot Study. [PDF]

Neurol Ther
Risi B, Ait Allali N, Cotti Piccinelli S, Caria F, Damioli S, Labella B, Bertella E, Giovanelli G, Garofali F, Margollicci G, Carugati R, Ferullo L, Olivieri E, Poli L, Padovani A, Filosto M.   +15 more
europepmc   +1 more source

Two distinct trajectories of brain volume loss in myotonic dystrophy type 1 via machine learning. [PDF]

Brain Commun
Imokawa T, Maki H, Sone D, Kagaya R, Shigemoto Y, Kimura Y, Matsuda H, Takahashi Y, Tateishi U, Sato N.   +9 more
europepmc   +1 more source

Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy. [PDF]

Cochrane Database Syst Rev
Annane D, Laberge L, Gallais B, Chevret S.   +3 more
europepmc   +1 more source

Characterization of <i>DMPK</i> and MBNL1 expression in cell models of myotonic dystrophy: a platform for drug screening. [PDF]

NAR Mol Med
López-Martínez A, Martín-González S, Torres-Conde N, Alcalá-Manso N, Al-Ani A, López de Munain A, Bigot A, Mamchaoui K, Nogales-Gadea G, Arechavala-Gomeza V.   +9 more
europepmc   +1 more source

Promoter-targeted small RNA duplexes increase MBNL1 transcription and mitigate myotonic dystrophy-associated spliceopathy. [PDF]

Nucleic Acids Res
Musiała-Kierklo N, Plewka P, Jasiok A, Stępniak-Konieczna E.   +3 more
europepmc   +1 more source